Business Description
DaVita Inc
NAICS : 621492
SIC : 8092
Description
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.04 | |||||
| Equity-to-Asset | 0.03 | |||||
| Debt-to-Equity | 22.6 | |||||
| Debt-to-EBITDA | 5.53 | |||||
| Interest Coverage | 4.41 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.4 | |||||
| Beneish M-Score | -2.76 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 16.9 | |||||
| 3-Year EBITDA Growth Rate | 22.3 | |||||
| 3-Year EPS without NRI Growth Rate | 35 | |||||
| 3-Year FCF Growth Rate | 37.1 | |||||
| 3-Year Book Growth Rate | -29.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 2.22 | |||||
| Future 3-5Y Total Revenue Growth Rate | 1.71 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 74.46 | |||||
| 9-Day RSI | 73.53 | |||||
| 14-Day RSI | 71.57 | |||||
| 6-1 Month Momentum % | -9.41 | |||||
| 12-1 Month Momentum % | -35.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.26 | |||||
| Quick Ratio | 1.22 | |||||
| Cash Ratio | 0.17 | |||||
| Days Inventory | 4.87 | |||||
| Days Sales Outstanding | 64.06 | |||||
| Days Payable | 18.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 16.4 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 29.7 | |||||
| Operating Margin % | 12.41 | |||||
| Net Margin % | 5.84 | |||||
| ROE % | 87.46 | |||||
| ROA % | 3.96 | |||||
| ROIC % | 7.13 | |||||
| ROC (Joel Greenblatt) % | 21.91 | |||||
| ROCE % | 9.89 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 12.57 | |||||
| Forward PE Ratio | 12.24 | |||||
| PE Ratio without NRI | 12.42 | |||||
| Shiller PE Ratio | 17.29 | |||||
| Price-to-Owner-Earnings | 11.08 | |||||
| PEG Ratio | 1.14 | |||||
| PS Ratio | 0.73 | |||||
| PB Ratio | 14.52 | |||||
| Price-to-Free-Cash-Flow | 7.29 | |||||
| Price-to-Operating-Cash-Flow | 4.82 | |||||
| EV-to-EBIT | 13.19 | |||||
| EV-to-Forward-EBIT | 12.91 | |||||
| EV-to-EBITDA | 8.87 | |||||
| EV-to-Forward-EBITDA | 8.76 | |||||
| EV-to-Revenue | 1.65 | |||||
| EV-to-Forward-Revenue | 1.64 | |||||
| EV-to-FCF | 16.7 | |||||
| Price-to-Projected-FCF | 0.46 | |||||
| Price-to-DCF (Earnings Based) | 0.61 | |||||
| Price-to-DCF (FCF Based) | 0.34 | |||||
| Price-to-Median-PS-Value | 0.62 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.75 | |||||
| Earnings Yield (Greenblatt) % | 7.58 | |||||
| Forward Rate of Return (Yacktman) % | 26.96 |
